Legend Biotech Corporation (NASDAQ: LEGN) reported clinical trial data for its investigational LB2501 therapy in patients with relapsed or refractory ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaJune 14, 2026 3:15 AM